. 2023 Sep 12;11:1218312. doi: 10.3389/fped.2023.1218312

Table 2.

Clinically inactive disease following treatment for the whole sJIA cohort (n = 76).

	3 months n = 76	12 months n = 63	Last follow-up n = 76
	3.1 months (2.7–3.8)	12 months (11.1–13.3)	4.7 years (2.2–9.2)
Clinically inactive disease^a (%)	44/76 (58%)	44/63 (70%)	67/76 (88%)
Treatment-free clinically inactive disease (remission; %)	3/76 (4%)	3/63 (5%)	24/76 (32%)
Glucocorticoid-free clinically inactive disease^b (%)	14/76 (18%)	36/63 (57%)	64/76 (84%)

Median age presented along with interquartile range (IQR). Absolute frequencies presented along with percentages.

^{^a}

Clinically inactive disease as per the modified Wallace criteria (25) irrespective of current treatment status.

^{^b}

Clinically inactive disease as per the modified Wallace criteria (25), off glucocorticoids (irrespective of other treatments received).